CUSIP: 85858C107
Q4 2017 13F Holders as of 31 Dec 2017
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
15,059,022
-
Share change
-
+2,193,292
-
Total reported value
-
$234,920,276
-
Put/Call ratio
-
67%
-
Price per share
-
$15.60
-
Number of holders
-
79
-
Value change
-
+$42,033,622
-
Number of buys
-
36
-
Number of sells
-
33
Quarterly Holders Quick Answers
What is CUSIP 85858C107?
CUSIP 85858C107 identifies STML - STEMLINE THERAPEUTICS INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q1 2018
-
Previous quarter:
Q3 2017
Recent filing periods for CUSIP 85858C107:
Institutional Holders of STEMLINE THERAPEUTICS INC - COM (STML) as of Q4 2017
As of 31 Dec 2017,
STEMLINE THERAPEUTICS INC - COM (STML) was held by
79 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
15,059,022 shares.
The largest 10 holders included
Consonance Capital Management LP, FMR LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., BlackRock Inc., EVENTIDE ASSET MANAGEMENT, LLC, Vanguard Group Inc, Lyon Street Capital, LLC, BAKER BROS. ADVISORS LP, AXA, and INTERNATIONAL BIOTECHNOLOGY TRUST PLC.
This page lists
79
institutional shareholders reporting positions in this security
for the Q4 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.